Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) – Drugs In Development, 2021

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) – Cathepsin L, a lysosomal endopeptidase is a member of the papain-like family of cysteine proteinases. Cathepsin L plays a major role in antigen processing, tumor invasion and metastasis, bone resorption, and turnover of intracellular and secreted proteins involved in growth regulation. Although commonly recognized as a lysosomal protease, cathepsin L is also secreted. The cathepsin L gene is activated by a variety of growth factors, tumor promoters, and second messengers. Cathepsin L promote tumor cell invasion and metastasis by catalyzing degradation of the interstitial matrix and basement membranes, thus allowing cancer cells to invade locally and metastasize to distant sites.

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) pipeline Target constitutes close to 6 molecules. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 2 and 3 respectively. Report covers products from therapy areas Infectious Disease and Oncology which include indications Coronavirus Disease 2019 (COVID-19), Breast Cancer, Chagas Disease (American Trypanosomiasis), Ebolavirus Infections (Ebola Hemorrhagic Fever), Head And Neck Cancer Squamous Cell Carcinoma, Marburgvirus Infections (Marburg Hemorrhagic Fever), Metastatic Prostate Cancer, Middle East Respiratory Syndrome (MERS), Osteosarcoma, Paramyxoviridae Infections and Severe Acute Respiratory Syndrome (SARS).

The latest report Cathepsin L1 – Drugs In Development, 2021, outlays comprehensive information on the Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)

– The report reviews Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics and enlists all their major and minor projects

– The report assesses Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Mateon Therapeutics Inc

Phelix Therapeutics LLC

Selva Therapeutics Inc

Vanda Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC

3.4.22.15) - Overview

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC

3.4.22.15) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC

3.4.22.15) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC

3.4.22.15) - Companies Involved in Therapeutics Development

Mateon Therapeutics Inc

Phelix Therapeutics LLC

Selva Therapeutics Inc

Vanda Pharmaceuticals Inc

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC

3.4.22.15) - Drug Profiles

Drugs to Inhibit Cathepsin L for Coronaviridae Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KGP-207 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KGP-420 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KGP-94 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLV-213 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Cathepsin-L for Coronavirus Disease 2019 (COVID-19) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC

3.4.22.15) - Dormant Products

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC

3.4.22.15) - Product Development Milestones

Featured News & Press Releases

Jul 19, 2021: Selva to present preclinical data at ASV 2021 demonstrating prophylactic and therapeutic oral dosing of SLV213 for COVID-19 protected lungs from SARS-CoV-2-induced damage

Jun 10, 2021: Selva’s Covid-19 drug shows activity against SARS-CoV-2 variants

Feb 03, 2021: Selva Therapeutics reports positive data from Covid-19 treatment trial

Nov 12, 2020: Selva Therapeutics announces first dosing in phase 1 clinical study of SLV213, a potential oral treatment for COVID-19

Mar 31, 2017: Mateon Therapeutics Announces Abstract Presentations for the American Association for Cancer Research Annual Meeting in April 2017

Apr 07, 2014: OXiGENE Announces Results of KGP94 Preclinical Studies at 2014 AACR Conference

Mar 27, 2014: OXiGENE Announces Presentation of Preclinical Abstracts at 2014 AACR Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Mateon Therapeutics Inc, 2021

Pipeline by Phelix Therapeutics LLC, 2021

Pipeline by Selva Therapeutics Inc, 2021

Pipeline by Vanda Pharmaceuticals Inc, 2021

Dormant Projects, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports